The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...
The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback